SOURCE: Conference Plus, Inc.

Conference Plus, Inc.

May 17, 2011 07:05 ET

Westell's ConferencePlus® Hosts Live Webcast "Social Media in Healthcare Marketing"

SCHAUMBURG, IL--(Marketwire - May 17, 2011) - Conference Plus, Inc. (ConferencePlus®), a subsidiary of Westell Technologies, Inc. (NASDAQ: WSTL), and a leading provider of global conferencing solutions, today announced a live webcast available to the public. This webcast is part of ConferencePlus' monthly Ask the Expert Webinar Series.

Scheduled for Thursday, May 19th, 2011 at 10:00 am (PDT)/12:00 noon (CDT)/1:00 pm (EDT), "Social Media in Healthcare Marketing" is targeted to healthcare and pharma marketers and is available to the public through ConferencePlus' Event Services. The live webcast will address questions from healthcare marketers on best practices for using social media while avoiding warning letters from the FDA.

This informative event comes at a time when healthcare and pharmaceutical marketers are awaiting FDA guidelines surrounding the use of digital marketing in the healthcare industry. The FDA's twice-delayed announcement of new guidelines for online and social media marketing leaves healthcare marketing professionals with no defined clarity on possible FDA constraints.

To address the current uncertainty in the industry, ConferencePlus will host two expert speakers to cover best practices for healthcare marketers. The main speaker, Tyler Pennock, Senior Vice President, Digital Media, Cohn & Wolfe, specializes in creating online strategies for healthcare clients that generate buzz and build relationships with patients, professionals and advocates. Tyler is joined by guest speaker and healthcare marketing leader Elizabeth Cermak, Executive Vice President, Chief Commercial Officer, POZEN Inc. Ms. Cermak will share her perspective on the evolution to "Pharma 3.0" and how her company is developing a commercial model that leverages digital platforms to engage key healthcare decision makers.

"While healthcare professionals await the FDA's new guidelines on digital marketing, it is important for the industry to innovate new ways of using web 2.0 technologies and social media to reach out to their audiences," said Dan Papa, Senior Vice President, Global Sales for ConferencePlus. "As companies evolve their marketing programs in the digital arena, our specialized Healthcare and Pharmaceutical Services team can help them reach their audience. We understand the medical industry and specialize in developing and delivering communication solutions to meet their needs," Mr. Papa added.

Join ConferencePlus' Healthcare & Pharmaceutical Services team for this live webcast on Thursday, May 19th, 2011, 10:00 am (PDT)/12:00 noon (CDT)/1:00 pm (EDT), "Social Media in Healthcare Marketing".

Use the following link to register for this complimentary live webcast event:

About Conference Plus, Inc.
Conference Plus, Inc., a leading global provider of audio, video, webcasting and web conferencing services, is dedicated to providing high quality, reliable conferencing services that customers trust with their most important events. ConferencePlus is leading the way in providing innovative IP-based collaboration solutions backed by proven technology and exceptional customer service. Headquartered in Schaumburg, Illinois with an international headquarters in Dublin, Ireland, ConferencePlus is a subsidiary of Westell Technologies, Inc. (NASDAQ: WSTL). Additional information about ConferencePlus can be obtained by visiting

About Westell Technologies, Inc.
Westell Technologies, Inc., headquartered in Aurora, Illinois, is a holding company for Westell, Inc. and Conference Plus, Inc. Westell, Inc. designs, distributes, markets and services a broad range of broadband networking equipment, digital transmission, remote monitoring, power distribution and demarcation products used by telephone companies and other telecommunications service providers. Additional information can be obtained by visiting

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years -- something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI toxicity. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit:

Contact Information